Gastro hep advances · 2025
Whole Exome Sequencing in Children With Autoimmune Hepatitis Identified Mutations in Genes Involved in the mTORC1 Signaling Pathway.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gaigne Léa-Philippine, Besnard Caroline, Debeaupuis Orianne, Degtiar Artem, Nhat Duong Ho, Stolzenberg Marie-Claude, Camara Fatou, Pellé Olivier, Schvartz Adrien, Perin Mélodie, Almes Marion, Darmellah-Remil Amaria, Gonzales Emmanuel, Gardin Antoine, Habes Dalila, Destombe Sylvie, De Martin Eleonora, Duclos-Vallée Jean-Charles, Arkwright Peter D, Rieux-Laucat Frédéric, Jacquemin Emmanuel, Magerus Aude
Аннотация
BACKGROUND AND AIMS: Autoimmune hepatitis (AIH), a severe immune-mediated liver disease resulting from defective immune tolerance, was thought to be caused by monogenic predisposition with possible external triggers. The development of AIH in monogenic primary immune deficiencies prompted us to search for causative genetic defects in AIH.
METHODS: Twenty-two children with AIH were included for whole exome sequencing analysis. Data were analyzed with an in-house software, combined with in silico tools and confirmed by Sanger sequencing. Mechanistic target of rapamycin (mTOR) pathway activation was assessed by phosphoS6-RP expression by fluorescence activated cells sorting.
RESULTS: In six children with type 1 or type 2 AIH, seven rare missense candidate variants with damaging predictive scores were identified in five genes involved in the regulation of the mTOR complex 1 (mTORC1) signaling pathway (RRAGC, LAMTOR3, MTOR, TSC2, and PRKAG1). Excess of phosphorylated-S6 ribosomal protein expression both ex vivo by monocytes and in vitro by activated T cells demonstrated an abnormal activation of mTORC1 in five out of six tested patients. Persistent mTORC1 activation in starved activated T cells could be abolished by mTOR inhibitor.
CONCLUSION: These data showed that pediatric patients with AIH-1 or AIH-2, especially when burdened with poly-autoimmunity, may carry mutations in key partners of the mTORC1 signaling pathway. Moreover, even without identified genetic defect, we observed a deregulation of the mTOR pathway in five out of six tested patients. These results shed new light on the pathogenesis of AIH. Moreover, they suggested that the patients could benefit from specific targeted agents such as mTOR inhibitors.
METHODS: Twenty-two children with AIH were included for whole exome sequencing analysis. Data were analyzed with an in-house software, combined with in silico tools and confirmed by Sanger sequencing. Mechanistic target of rapamycin (mTOR) pathway activation was assessed by phosphoS6-RP expression by fluorescence activated cells sorting.
RESULTS: In six children with type 1 or type 2 AIH, seven rare missense candidate variants with damaging predictive scores were identified in five genes involved in the regulation of the mTOR complex 1 (mTORC1) signaling pathway (RRAGC, LAMTOR3, MTOR, TSC2, and PRKAG1). Excess of phosphorylated-S6 ribosomal protein expression both ex vivo by monocytes and in vitro by activated T cells demonstrated an abnormal activation of mTORC1 in five out of six tested patients. Persistent mTORC1 activation in starved activated T cells could be abolished by mTOR inhibitor.
CONCLUSION: These data showed that pediatric patients with AIH-1 or AIH-2, especially when burdened with poly-autoimmunity, may carry mutations in key partners of the mTORC1 signaling pathway. Moreover, even without identified genetic defect, we observed a deregulation of the mTOR pathway in five out of six tested patients. These results shed new light on the pathogenesis of AIH. Moreover, they suggested that the patients could benefit from specific targeted agents such as mTOR inhibitors.